UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

Dow Jones

Mar 02

By Adriano Marchese

UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective.

Shares traded 42% lower ahead of the morning bell at $9.

The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130.

Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain.

UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study.

The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 02, 2026 07:58 ET (12:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2616332185"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616332185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616332185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616332185","market":"fut","top_or_hot":-1,"title":"UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective. \n</p>\n<p>\n  Shares traded 42% lower ahead of the morning bell at $9. \n</p>\n<p>\n  The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130. \n</p>\n<p>\n  Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain. \n</p>\n<p>\n  UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study. \n</p>\n<p>\n  The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 07:58 ET (12:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-02 20:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective. \n</p>\n<p>\n  Shares traded 42% lower ahead of the morning bell at $9. \n</p>\n<p>\n  The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130. \n</p>\n<p>\n  Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain. \n</p>\n<p>\n  UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study. \n</p>\n<p>\n  The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 07:58 ET (12:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616332185","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616332185","pubTimestamp":1772456280,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective.Shares traded 42% lower ahead of the morning bell at $9.The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130.Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain.UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study.The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to disc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","QURE":"uniQure N.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"FDA称亨廷顿基因治疗数据不足，UniQure上市前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective. \n\n\n  Shares traded 42% lower ahead of the morning bell at $9. \n\n\n  The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130. \n\n\n  Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain. \n\n\n  UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study. \n\n\n  The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 07:58 ET (12:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}